Podcast

Having a choice is empowering when you have trustworthy information before.

In this episode of the HLTH Matters Podcast, Silvia Taylor, executive vice president and chief communications officer for Novavax, talks about making scientific information accessible to people, especially around the COVID-19 vaccines. Novavax developed a safe COVID-19 vaccine during the pandemic and ensures people have the information they need to make an informed choice about their vaccination worldwide. Silvia shares her insights on the relationships and partnerships Novavax has to deliver that necessary information to points of care in the ever-evolving healthcare market. She also encourages listeners to get informed, talk to their providers, and vaccinate against COVID-19.

Learn more about Novavax and Silvia’s work to make scientific health information accessible to people with this episode! 

About Silvia Taylor:

Silvia Taylor is executive vice president, chief communications officer for Novavax. Ms. Taylor has responsibility for investor relations; public relations; external and internal communications; corporate social responsibility and ESG (environmental, social, and governance) strategy; digital and social media; and meetings, events, and corporate merchandising for the company. She brings more than 25 years of communications and commercial leadership to Novavax. Most recently, she was vice president of global corporate affairs and communications at Autolus Therapeutics plc, where sheled all financial, scientific, and corporate communications. Prior to Autolus, Ms. Taylor was senior vice president of global investor relations and corporate affairs at Sucampo. Earlier in her career, she held positions of increasing responsibility at MedImmune LLC, the global biologics arm of AstraZeneca, including head of marketing, responsible for the commercialization of the company’s respiratory syncytial virus and influenza franchises, as well as at Pfizer, where she served in key brand and consumer marketing roles. Ms. Taylor earned a Master of Business Administration degree from Columbia University and a Bachelor of Arts degree in foreign affairs from University of Virginia. In 2022, she was elected to the Page Society, a membership organization of chief communications officers of global Fortune-ranked corporations.

Things You’ll Learn:

• People aren’t scientists, but they consume science all day long. 
• Novavax is a biotechnology company that makes vaccines and has a platform for adjuvanted protein-based vaccines.
• Novavax is available in many countries worldwide and authorized in over 43.
• During 2020 and 2021, there was a lot of fear and misinformation about vaccines regarding their safety and development process.
• The COVID-19 pandemic is not over yet, and people shouldn’t act as if it was.
• Governments are Novavax’s primary customers.
• During the pandemic, people accessed vaccines in large numbers at pharmacies, which will probably not change.

Resources:

• Connect with and follow Silvia Taylor on LinkedIn.
• Follow Novavax on LinkedIn.
• Visit the Novavax Website!
• Find out more about the COVID-19 vaccines at vaccines.gov.